← Back to Search

Topoisomerase I inhibitors

Etoposide for Small Cell Lung Cancer (Drugs-SNPs Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of Small Cell Lung Cancer (SCLC)
Suitable for enough lung tissue biopsy of SCLC
Screening 3 weeks
Treatment Varies
Follow Up duration at least 90 days
Awards & highlights

Drugs-SNPs Trial Summary

This trial will explore the relationship between a patient's genetic makeup and how well they respond to the drug etoposide, as well as any side-effects they may experience.

Who is the study for?
This trial is for adults over 22 with small cell lung cancer who can undergo a biopsy and have their blood drawn. They must be able to sign consent, have measurable disease, good organ function and performance status. It's not for those with serious allergies to drugs, multiple cancers, severe bleeding risks or infections, pregnant or breastfeeding individuals.Check my eligibility
What is being tested?
The study investigates how genetic differences (SNPs) in the topoisomerase II gene and CYP4503A4 gene affect the treatment outcomes and side effects of Etoposide in small cell lung cancer patients. The trial uses precise gene sequencing techniques.See study design
What are the potential side effects?
Etoposide may cause low white blood cell counts (increasing infection risk), hair loss, nausea, vomiting, diarrhea or constipation. There might also be allergic reactions like rashes or more serious ones that could require immediate medical attention.

Drugs-SNPs Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with Small Cell Lung Cancer.
My doctor can take a biopsy of my lung tissue.
My lung cancer was confirmed through a tissue biopsy.
I am 22 years old or older.

Drugs-SNPs Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration at least 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration at least 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated.

Drugs-SNPs Trial Design

2Treatment groups
Experimental Treatment
Group I: ETOPOSIDE - UsualExperimental Treatment1 Intervention
Etoposide Injection Chemotherapy Etoposide Injection Usual Approach Group
Group II: ETOPOSIDE - StudyExperimental Treatment1 Intervention
Etoposide Capsule Chemotherapy Etoposide Capsule Study Approach Group

Find a Location

Who is running the clinical trial?

Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB ChairLead Sponsor
3 Previous Clinical Trials
640 Total Patients Enrolled
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairLead Sponsor
5 Previous Clinical Trials
1,840 Total Patients Enrolled
2 Previous Clinical Trials
592,548 Total Patients Enrolled

Media Library

Etoposide (Topoisomerase I inhibitors) Clinical Trial Eligibility Overview. Trial Name: NCT01064466 — Phase 2 & 3
Small Cell Lung Cancer Research Study Groups: ETOPOSIDE - Study, ETOPOSIDE - Usual
Small Cell Lung Cancer Clinical Trial 2023: Etoposide Highlights & Side Effects. Trial Name: NCT01064466 — Phase 2 & 3
Etoposide (Topoisomerase I inhibitors) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01064466 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Would it be possible for me to participate in this clinical trial?

"This clinical trial is looking for 600 participants with small cell lung carcinoma, aged 22 to 75. In order to be eligible, patients must have had the condition for at least 180 days and must be able to have a lung tissue biopsy. Additionally, the following criteria must be met: 1. Clinical diagnosis of Small cell lung cancer (SCLC), 2. Clinical lung tissue biopsy diagnosis of SCLC, 3. Suitable for enough lung tissue biopsy of SCLC, 4. Random and double blind, 5. Measurable disease, 6. Adequate organ functions."

Answered by AI

What conditions does ETOPOSIDE - Study help treat?

"ETOPOSIDE - This medication is most frequently utilized to manage small cell lung cancer (sclc). Additionally, it can be useful in treating metastatic thymic cancer, leukemia, myelocytic, acute, and advance directives."

Answered by AI

Can people below the age of 20 participate in this clinical research?

"The age limit for this study are individuals who are at least 22 but no older than 75."

Answered by AI

What does the research say about using etoposide to treat patients?

"There are presently 322 clinical trials underway researching the efficacy of ETOPOSIDE - Study. 95 of those are in the final Phase 3. Many of these studies are based in Houston, Texas, but there are a total of 15464 locations running these trials."

Answered by AI

Do we have the regulatory go-ahead to use ETOPOSIDE in this research?

"ETOPOSIDE - Study has been scored a 3 for safety by our team at Power. This is due to this being a Phase 3 trial, which signifies that there is data affirming its efficacy as well as multiple rounds of data affirming its safety."

Answered by AI
~45 spots leftby Nov 2024